Ignite Creation Date:
2025-12-24 @ 4:09 PM
Ignite Modification Date:
2025-12-24 @ 4:09 PM
Study NCT ID:
NCT06757166
Status:
RECRUITING
Last Update Posted:
2025-01-03
First Post:
2024-12-23
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
The Effect of NOn-invasive Respiratory Support on outcoMe and Its Risks in SARS-COV-2-related Hypoxemic Respiratory Failure
Sponsor:
Erasmus Medical Center
Organization:
Study Overview
Official Title:
Effects of Early vs. Delayed Invasive Mechanical Ventilation: A Target Trial Emulation
Status:
RECRUITING
Status Verified Date:
2025-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NORMO2
Brief Summary:
To determine whether early endotracheal intubation compared to late endotracheal intubation affects clinical outcome (duration of invasive mechanical ventilation, mortality).
Detailed Description:
Non-invasive respiratory support, especially HFNO is usually well-tolerated, especially in COVID-19 patients and can be applied for a prolonged period of time. However, there is a heated debate whether later/delayed endotracheal intubation (due to HFNO / NIV) increases the risk of lung injury, so-called patient self-inflicted lung-injury (P-SILI). The concept of P-SILI assumes that high forces applied to the lung resulting from strenuous breathing effort generated by the patient exacerbates lung-injury and is associated with adverse clinical outcome. It is therefore important to investigate if a longer period of non-invasive respiratory support before invasive mechanical ventilation is associated with adverse clinical outcome. Thus, it is unknown if delaying invasive ventilation worsens clinical outcome. In this study, the research question is whether early compared to late endotracheal intubation improves clinical outcome (duration of invasive mechanical ventilation, mortality)? The aim is to identify the optimal S/F ratio and respiratory rate thresholds for initiating intubation to either improve survival or reduce the duration of invasive ventilation without compromising survival. This is achieved by comparing 25 dynamic treatment regimes defined by combinations of S/F thresholds (\<any, 250, 200, 150, 100) and respiratory rate thresholds (\>any, 16, 20, 25, 30). Thresholds indicating less severe illness (e.g., S/F \< 250 and RR \> 16) are considered 'early intubation,' while thresholds indicating more severe illness (e.g., S/F \< 100 and RR \> 30) are considered 'late intubation'.
Two sensitivity analyses will be conducted:
1. Restricting to patients without hypercapnia (pCO2 \< 45), excluding those with missing pCO2 values or pCO2 \> 45.
2. Including only patients with non-missing Glasgow Coma Scale (GCS) values and adjusting for GCS as a confounder.
Additionally, seven subgroup analyses will be conducted:
1. Patients diagnosed with COVID-19
2. Patients with a history of COPD
3. Patients with a history of CHF
4. Patients with BMI ≤ 30
5. Patients with BMI \> 30
6. Patients on high-flow nasal oxygen (HFNO) at time zero
7. Patients on non-invasive ventilation (NIV) at time zero
Two sensitivity analyses will be conducted:
1. Restricting to patients without hypercapnia (pCO2 \< 45), excluding those with missing pCO2 values or pCO2 \> 45.
2. Including only patients with non-missing Glasgow Coma Scale (GCS) values and adjusting for GCS as a confounder.
Additionally, seven subgroup analyses will be conducted:
1. Patients diagnosed with COVID-19
2. Patients with a history of COPD
3. Patients with a history of CHF
4. Patients with BMI ≤ 30
5. Patients with BMI \> 30
6. Patients on high-flow nasal oxygen (HFNO) at time zero
7. Patients on non-invasive ventilation (NIV) at time zero
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: